TAMPA (BLOOM) – Taking care of your pet’s teeth is just as crucial as caring for your own, yet it’s an aspect of pet health that can sometimes be overlooked. Proper oral hygiene can prevent a slew of health issues and even extend your furry friend’s life. Here’s how you can keep your pet’s chompers […]
Japanese drugmaker Eisai and US-based Biogen have received FDA approval for Leqembi, making it the first approved treatment available that can slow the progression of Alzheimer’s in patients.
the decision could have other applications, including who could access. cnn medical correspondent make terrel explains. reporter: six years ago, joe saw a neurologist for what he thought were a few minor problems with his memory. i came back and that you know what, joe, you know it, you have younger onset alzheimer s. you are likely going to experience declines the next five years. you may not recognize your family in 5 to 7 years. now 59, and is one of millions of americans living with all-time disease. this year, new hope emerged, a drug aiming to slow down the disease s progression got accelerated fda approval in january based on the fact that it clears plaque buildup in the brain associated with all timers. medicare declined to cover it until the fda granted a additional approval based on a bigger clinical trial, proven the drug benefits for thinking clearly. without insurance, the medicine
significantly slowed cognitive decline. according to the company s latest clinical trials, some people who took the drug slowed their decline by up to 35% compared to those who took a placebo. the study included 1,700 participants between the age of 60 and 85. joining us now is meg terrell. this means so much to so many people. we ve seen how many people are struggling with this. the question is, how legit is this study? it s extremely legit. in terms of running clinical trials, a phase iii placebo-controlled study is the gold standard. this was run with a lot of patients. lily will use this to file for fda approval this quarter. what this drug does is it s the latest in a new group that is successfully removing amyloid plaques from the brain. you can see in this graphic, the top two images are patients on this drug. this is an earlier study. over the course of 76 weeks, that plaque buildup in the